CBD

CBD staat voor Cannabidiol. Dit is één van de cannabinoïden die ons lichaam zelf aanmaakt. Een cannabinoïde is een stof die zich bindt aan een receptor. Dat is simpel gezegd een eiwit dat onderdeel is van bijvoorbeeld een cel en dat door de binding met de cannabinoïde een bepaald proces in gang zet.

De processen

Onderzoeken tonen aan dat cannabinoïden allerlei processen in gang zetten, afhankelijk van de receptor waarmee het zich bindt. Als we alleen kijken naar de resultaten dan zijn die inderdaad indrukwekkend of op zijn minst hoopgevend.

Planten

Cannabidiol komt ook voor in planten, met name in Cannabis. De gunstige effecten van cannabis zijn al eeuwen bekend. 4000 jaar voor Christus werd het door Chinezen al gebruikt als medicijn. 1000 Jaar voor Christus gebruikten de Romeinen, Grieken en Arabieren het om diverse medische redenen.
Maar de werking was lange tijd onbekend. Rond 1935 werden de twee belangrijkste cannabinoïden ontdekt, cannabidiol (CBD) en cannabinol (CBN). Inmiddels is bekend dat cannabis uit ruim 400 stoffen bestaat, waarvan er ruim 85 als cannabinoïde zijn herkend.

Cannabinoïden in het lichaam

Het lichaam maakt zelf cannabinoïden aan. Tezamen met de bijbehorende receptoren zijn ze overal in het lichaam gevonden, zoals in de hersenen, de organen en klieren en in immuuncellen. Op al die plekken voert het specifieke processen (taken) uit.

Fytocannabinoïde systeem

Er is veel onderzoek gedaan met cannabinoïden uit cannabis. Daaruit blijkt dat de cannabinoïden uit planten, het zogenaamde fytocannabinoïde systeem, helpen het lichaamseigen proces te stimuleren.
Uit onderzoek blijkt dat een kleine dosis cannabis of CBD het lichaam aanzet tot het zelf aanmaken van meer endocannabinoïden en de bijbehorende eiwitten (receptoren).

Publicaties onderzoeken Cannabidiol (CBD)

Hier vindt u verschillende publicaties over CBD, gesorteerd naar ziektebeeld. Door de URL te kopiëren in uw browser komt u op de website van het National Center for Biotechnology Information.

ADD / ADHD
Cannabidiol and clozapine reverse MK-801-induced deficits in social interaction and
hyperactivity in Sprague-Dawley rats.
http://www.ncbi.nlm.nih.gov/pubmed/22495620

Addiction
Cannabidiol reduces cigarette consumption in tobacco smokers
http://www.ncbi.nlm.nih.gov/pubmed/23685330

AIDS
Cannabidiol inhibits growth and induces programmed cell death in kaposi sarcoma-
associated herpesvirus-infected endothelium
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3527984/

ALS
Cannabis and amyotrophic lateral sclerosis: hypothetical and practical applications,
and a call for clinical trials.
http://www.ncbi.nlm.nih.gov/pubmed/20439484

Alzheimer’s
Cannabidiol: a promising drug for neurodegenerative disorders?
http://www.ncbi.nlm.nih.gov/pubmed/19228180

Anorexia
Leptin, ghrelin, and endocannabinoids: potential therapeutic targets in anorexia
nervosa.
http://www.ncbi.nlm.nih.gov/pubmed/18926548

Antibiotic resistance
Antibacterial activity of delta9-tetrahydrocannabinol and cannabidiol.
http://www.ncbi.nlm.nih.gov/pubmed/1085130

Anxiety
Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug.
http://www.ncbi.nlm.nih.gov/pubmed/22729452

Atherosclerosis
The role of the endocannabinoid system in atherosclerosis.
http://www.ncbi.nlm.nih.gov/pubmed/18426500

Arthritis
The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic
therapeutic in murine collagen-induced arthritis.
http://www.ncbi.nlm.nih.gov/pubmed/10920191

Asthma
The role of eannabinoids in inflammatory modulation of allergie respiratory
disorders, inflammatory pain and ischemie stroke.
htlp://www.ncbi.nlm.nih.gov/pubmed/22420307

Autism
Targeting the endoeannabinoid system in the treatment of fragile X syndrome.
http://www.ncbi.nlm.nih.gov/pubmed/23542787

Bipolar
Cannabinoids in bipolar affeetive disorder: a review and discussion of their
therapeutie potential.
http://www.ncbi.nlm.nih.gov/pubmed/15888515

Cancer
Cannabidiol as potential anticancer drug.
http://www.ncbi.nlm.nih.gov/pubmed/22506672

Colitis / Crohn’s
Cannabidiol in inflammatory bowel diseases: a brief overview.
http://www.ncbi.nlm.nih.gov/pubmed/22815234

Depression
Antidepressant-like effects of eannabidiol in miee: possible involvement of 5-HT1 A
receptors.
http://www.ncbi.nlm.nih.gov/pubmed/20002102

Diabetes
Cannabidiol arrests onset of autoimmune diabetes in NOO mice.
http://www.ncbi.nlm.nih.gov/pubmed/17714746

Endocrine disorders
Endocannabinoid system participates in neuroendocrine contral of homeostasis.
http://www.ncbi.nlm.nih.gov/pubmed/20134190

Epilepsy / seizure
Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and
partial seizures.
http://www.ncbi.nlm.nih.gov/pubmed/22520455

Fibromyalgia
Clinical endocannabinoid deficiency (CECD): can this concept explain therapeut ic
benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other
treatment-resistant conditions?
http://www.ncbi.nlm.nih.gov/pubmed/18404144

Glaucoma
Effect of sublingual application of cannabinoids on intraocular pressure: a pilot
study.
http://www.ncbi.nlm.nih.gov/pubmed/16988594

Heart disease
Is the cardiovascular system a therapeutic target for cannabidiol?
http://www.ncbi.nlm.nih.gov/pubmed/22670794

Huntington’s
Cannabinoids: novel medicines tor the treatment of Huntington’s disease.
http://www.ncbi.nlm.nih.gov/pubmed/22280340

Inflammation
Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress.
http://www.ncbi.nlm.nih.gov/pubmed/21238581

Irritable bowel Syndrome
Cannabidiol in inflammatory bowel diseases: a brief overview.
http://www.ncbi.nlm.nih.gov/pubmed/22815234

Kidney disease
Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/
nitrosative stress, inflammation, and cell death.
http://www.ncbi.nlm.nih.gov/pubmed/19074681

Liver disease
The endocannabinoid system and liver diseases.
http://www.ncbi.nlm.nih.gov/pubmed/18426499

Metabolic syndrome
The potential use of cannabidiol in the therapy of metabolic syndrome
http://www.ncbi.nlm.nih.gov/pubmed/22430005

Migraine
Effects of anandamide in migraine: data from an animal model.
http://www.ncbi.nlm.nih.gov/pubmed/21331757

Mood disorders
The endocannabinoid system and the treatment of mood and anxiety disorders.
http://www.ncbi.nlm.nih.gov/pubmed/19839936

Motion sickness
Motion sickness, stress and the endocannabinoid system.
http://www.ncbi.nlm.nih.gov/pubmed/20505775

Multiple sclerosis
Sativex for the management of multiple sclerosis symptoms.
http://www.ncbi.nlm.nih.gov/pubmed/16317825

Nausea
Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and
nausea-like behaviour via indirect agonism of 5-HT(1 A) somatodendritic
autoreceptors in the dorsal rap he nucleus.
http://www.ncbi.nlm.nih.gov/pubmed/21827451

Neurodegeneration
Cannabidiol: a promising drug tor neurodegenerative disorders?
http://www.ncbi.nlm.nih.gov/pubmed/19228180

Neuropathie pain
Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-
related pain.
http://www.ncbi.nlm.nih.gov/pubmed/17257464

Obesity
Cannabinol and cannabidiol exert opposing effects on rat feeding patterns.
http://www.ncbi.nlm.nih.gov/pubmed/22543671

OCD
Plasma and brain pharmacokinetic profile of cannabidiol (CSD), cannabidivarine
(CBDV), A9-tetrahydrocannabivarin (THCV) and cannabigerol (CSG) in rats and mice
following oral and intraperitoneal administration and CSD action on obsessive-
compulsive behaviour.
http://www.ncbi.nlm.nih.gov/pubmed/21796370

Osteoporosis
Cannabinoid receptors as target for treatment of osteoporosis: a tale of two
therapies.
http://www.ncbi.nlm.nih.gov/pubmed/21358974

Parkinson’s
Cannabidiol for the treatment of psychosis in Parkinson’s disease.
http://www.ncbi.nlm.nih.gov/pubmed/18801821

Mad Cow disease
Nonpsychoactive cannabidiol prevents prion accumulation and protects neurons
against prion toxicity.
http://www.ncbi.nlm.nih.gov/pubmed/17804615

Rheumatism
Cannabidiol as an emergent therapeutic strategy for lessening the impact of
inflammation on oxidative stress.
http://www.ncbi.nlm.nih.gov/pubmed/21238581

Schizophrenia
Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.
http://www.ncbLnlm.nih.gov/pubmed/16612464

Siekle eell anemia
Pain-related behaviors and neurochemical alterations in mice expressing sickie
hemoglobin: modulation by cannabinoids.
http://www.ncbi.nlm.nih.gov/pubmed/20304807

Skin conditions
The endocannabinoid system of the skin in health and disease: novel perspectives
and therapeutic opportunities.
http://www.ncbi.nlm.nih.gov/pubmed/19608284

Sleep disorders
The nonpsychoactive Cannabis constituent cannabidiol is a wake-inducing agent.
http://www.ncbi.nlm.nih.gov/pubmed/19045957

Spinal cord injury
Cannabidiol-treated rats exhibited higher motor score after cryogenic spinel cord
injury.
http://www.ncbi.nlm.nih.gov/pubmed/21915768

Stress
The anxiolytic effect of cannabidiol on chronically stressed mice depends on
hippocampal neurogenesis: involvement of the endocannabinoid system.
http://www.ncbi.nlm.nih.gov/pubmed/23298518

Stroke / TBI
Cannabidiol, a nonpsychoactive Cannabis constituent, protects against myocardial
ischemie reperfusion injury.
http://www.ncbi.nlm.nih.gov/pubmed/17890433

Bronnen

GPR55 promotes migration and adhesion of colon cancer cells indicating a role in metastasis. Kargl J, Andersen L, Hasenöhrl C, Feuersinger D, Stančić A, Fauland A, Magnes C, El-Heliebi A, Lax S, Uranitsch S, Haybaeck J, Heinemann A, Schicho R. Br J Pharmacol. 2015 Oct 5. doi: 10.1111/bph.13345.
Polypharmacology Shakes Hands with Complex Aetiopathology. Brodie JS, Di Marzo V, Guy GW. Trends Pharmacol Sci. 2015 Sep 18. pii: S0165-6147(15)00171-6. doi: 10.1016/j.tips.2015.08.010.
Cannabinoids, cannabinoid receptors and tinnitus. Smith PF, Zheng Y. Hear Res. 2015 Sep 30. pii: S0378-5955(15)30036-8. doi: 10.1016/j.heares.2015.09.014.
Analysis of Cannabinoids and Their Metabolites in Human Urine. Wei B, Wang L, Blount BC. Anal Chem. 2015 Oct 5.
Endocannabinoids and the Digestive Tract and Bladder in Health and Disease. Izzo AA, Muccioli GG, Ruggieri MR, Schicho R. Handb Exp Pharmacol. 2015;231:423-47. doi: 10.1007/978-3-319-20825-1_15.
Cannabis and Endocannabinoid Signaling in Epilepsy. Katona I. Handb Exp Pharmacol. 2015;231:285-316. doi: 10.1007/978-3-319-20825-1_10.
Neural correlates of cannabidiol and Δ9-tetrahydrocannabinol interactions in mice: implications for medical cannabis. Todd SM, Arnold JC. Br J Pharmacol. 2015 Sep 17. doi: 10.1111/bph.13333.
Wittig derivatization of sesquiterpenoid polygodial leads to cytostatic agents with activity against drug resistant cancer cells and capable of pyrrolylation of primary amines. Dasari R, De Carvalho A, Medellin DC, Middleton KN, Hague F, Volmar MN, Frolova LV, Rossato MF, De La Chapa JJ, Dybdal-Hargreaves NF, Pillai A, Kälin RE, Mathieu V, Rogelj S, Gonzales CB, Calixto JB, Evidente A, Gautier M, Munirathinam G, Glass R, Burth P, Pelly SC, van Otterlo WA, Kiss R, Kornienko A. Eur J Med Chem. 2015 Oct 20;103:226-37. doi: 10.1016/j.ejmech.2015.08.047. Epub 2015 Aug 29.
Cannabinoids in the Treatment of Epilepsy. Friedman D, Devinsky O. N Engl J Med. 2015 Sep 10;373(11):1048-58. doi: 10.1056/NEJMra1407304
Cannabidiol and Sodium Nitroprusside: Two Novel Neuromodulatory Pharmacological Interventions to Treat and Prevent Psychosis. Crippa JA, Hallak JE, Abilio VC, de Lacerda AL, Zuardi AW. CNS Neurol Disord Drug Targets. 2015;14(8):970-8.
Flax Fiber Hydrophobic Extract Inhibits Human Skin Cells Inflammation and Causes Remodeling of Extracellular Matrix and Wound Closure Activation. Styrczewska M, Kostyn A, Kulma A, Majkowska-Skrobek G, Augustyniak D, Prescha A, Czuj T, Szopa J. Biomed Res Int. 2015;2015:862391. doi: 10.1155/2015/862391. Epub 2015 Aug 4.
Cannabidiol as a Potential Treatment for Anxiety Disorders. Blessing EM, Steenkamp MM, Manzanares J, Marmar CR. Neurotherapeutics. 2015 Sep 4.
Medical Marijuana and Chronic Pain: a Review of Basic Science and Clinical Evidence. Altering Rules on Cannabidiol Therapies. Toth Z. State Legis. 2015 Sep;41(8):11. No abstract available.
Cannabinoids and Schizophrenia: Risks and Therapeutic Potential. Manseau MW, Goff DC. Neurotherapeutics. 2015 Aug 27.
High dosage of cannabidiol (CBD) alleviates pentylenetetrazole-induced epilepsy in rats by exerting an anticonvulsive effect. Mao K, You C, Lei D, Zhang H. Int J Clin Exp Med. 2015 Jun 15;8(6):8820-7. eCollection 2015.
E-Cigarettes: A Review of New Trends in Cannabis Use. Giroud C, de Cesare M, Berthet A, Varlet V, Concha-Lozano N, Favrat B. Int J Environ Res Public Health. 2015 Aug 21;12(8):9988-10008. doi: 10.3390/ijerph120809988.
Marijuana Use in Epilepsy: The Myth and the Reality. Detyniecki K, Hirsch L. Curr Neurol Neurosci Rep. 2015 Oct;15(10):586. doi: 10.1007/s11910-015-0586-5.
Mechanisms of vasorelaxation induced by the cannabidiol analogue compound O-1602 in the rat small mesenteric artery. Al Suleimani YM, Al Mahruqi AS, Hiley CR. Eur J Pharmacol. 2015 Aug 18;765:107-114. doi: 10.1016/j.ejphar.2015.08.021.
Sativex® and clinical-neurophysiological measures of spasticity in progressive multiple sclerosis. Leocani L, Nuara A, Houdayer E, Schiavetti I, Del Carro U, Amadio S, Straffi L, Rossi P, Martinelli V, Vila C, Sormani MP, Comi G. J Neurol. 2015 Aug 20.
MK-801-induced deficits in social recognition in rats: reversal by aripiprazole, but not olanzapine, risperidone, or cannabidiol. Deiana S, Watanabe A, Yamasaki Y, Amada N, Kikuchi T, Stott C, Riedel G. Behav Pharmacol. 2015 Aug 18.
Cannabidiol, a Cannabis sativa constituent, inhibits cocaine-induced seizures in mice: Possible role of the mTOR pathway and reduction in glutamate release. Gobira PH, Vilela LR, Gonçalves BD, Santos RP, de Oliveira AC, Vieira LB, Aguiar DC, Crippa JA, Moreira FA. Neurotoxicology. 2015 Aug 15;50:116-121. doi: 10.1016/j.neuro.2015.08.007.
Cannabinoids and Epilepsy. Rosenberg EC, Tsien RW, Whalley BJ, Devinsky O. Neurotherapeutics. 2015 Aug 18.
HU-444, a Novel, Potent Anti-Inflammatory, Nonpsychotropic Cannabinoid. Haj CG, Sumariwalla PF, Hanuš L, Kogan NM, Yektin Z, Mechoulam R, Feldmann M, Gallily R. J Pharmacol Exp Ther. 2015 Oct;355(1):66-75. doi: 10.1124/jpet.115.226100. Epub 2015 Aug 13.
Cannabis in the Treatment of Dystonia, Dyskinesias, and Tics. Koppel BS. Neurotherapeutics. 2015 Aug 14.
Early Phase in the Development of Cannabidiol as a Treatment for Addiction: Opioid Relapse Takes Initial Center Stage. Hurd YL, Yoon M, Manini AF, Hernandez S, Olmedo R, Ostman M, Jutras-Aswad D. Neurotherapeutics. 2015 Aug 13.[Clinical pharmacology of medical cannabinoids in chronic pain]. Ing Lorenzini K, Broers B, Lalive PH, Dayer P, Desmeules J, Piguet V. Rev Med Suisse. 2015 Jun 24;11(480):1390, 1392-4. French.
Molecular Targets of Cannabidiol in Neurological Disorders. Ibeas Bih C, Chen T, Nunn AV, Bazelot M, Dallas M, Whalley BJ. Neurotherapeutics. 2015 Aug 12.
HU-446 and HU-465, Derivatives of the Non-psychoactive Cannabinoid Cannabidiol, Decrease the Activation of Encephalitogenic T Cells. Kozela E, Haj C, Hanuš L, Chourasia M, Shurki A, Juknat A, Kaushansky N, Mechoulam R, Vogel Z. Chem Biol Drug Des. 2015 Aug 11. doi: 10.1111/cbdd.12637.
Cannabinoid Concentrations Detected in Fatal Road Traffic Collision Victims Compared with a Population of Other Postmortem Cases. Andrews R, Murphy KG, Nahar L, Paterson S. Clin Chem. 2015 Oct;61(10):1256-64. doi: 10.1373/clinchem.2015.240846. Epub 2015 Aug 3.
Pharmacological profiling of the hemodynamic effects of cannabinoid ligands: a combined in vitro and in vivo approach. Walsh SK, Hepburn CY, Keown O, Åstrand A, Lindblom A, Ryberg E, Hjorth S, Leslie SJ, Greasley PJ, Wainwright CL. Pharmacol Res Perspect. 2015 Jun;3(3):e00143. doi: 10.1002/prp2.143. Epub 2015 May 8.
Potency trends of Δ9 -tetrahydrocannabinol, cannabidiol and cannabinol in cannabis in the Netherlands: 2005-15. Niesink RJ, Rigter S, Koeter MW, Brunt TM. Addiction. 2015 Aug 1. doi: 10.1111/add.13082.
Cannabidiol is a negative allosteric modulator of the type 1 cannabinoid receptor. Laprairie RB, Bagher AM, Kelly ME, Denovan-Wright EM. Br J Pharmacol. 2015 Jul 27. doi: 10.1111/bph.13250.
Examining the profile of high-potency cannabis and its association with severity of cannabis dependence. Freeman TP, Winstock AR. Psychol Med. 2015 Jul 27:1-9.
Effect of Non-psychotropic Plant-derived Cannabinoids on Bladder Contractility: Focus on Cannabigerol. Pagano E, Montanaro V, Di Girolamo A, Pistone A, Altieri V, Zjawiony JK, Izzo AA, Capasso R. Nat Prod Commun. 2015 Jun;10(6):1009-12.
Gene duplication and divergence affecting drug content in Cannabis sativa. Weiblen GD, Wenger JP, Craft KJ, ElSohly MA, Mehmedic Z, Treiber EL, Marks MD. New Phytol. 2015 Jul 17. doi: 10.1111/nph.13562.
Influence of single and repeated cannabidiol administration on emotional behavior and markers of cell proliferation and neurogenesis in non-stressed mice. Schiavon AP, Bonato JM, Milani H, Guimarães FS, Weffort de Oliveira RM. Prog Neuropsychopharmacol Biol Psychiatry. 2016 Jan 4;64:27-34. doi: 10.1016/j.pnpbp.2015.06.017. Epub 2015 Jul 14.
Cannabidiol induces expression of human cytochrome P450 1A1 that is possibly mediated through aryl hydrocarbon receptor signaling in HepG2 cells. Yamaori S, Kinugasa Y, Jiang R, Takeda S, Yamamoto I, Watanabe K. Life Sci. 2015 Sep 1;136:87-93. doi: 10.1016/j.lfs.2015.07.007. Epub 2015 Jul 15.
Pressurized liquid extraction for the determination of cannabinoids and metabolites in hair: Detection of cut-off values by high performance liquid chromatography-high resolution tandem mass spectrometry. Montesano C, Simeoni MC, Vannutelli G, Gregori A, Ripani L, Sergi M, Compagnone D, Curini R. J Chromatogr A. 2015 Aug 7;1406:192-200. doi: 10.1016/j.chroma.2015.06.021. Epub 2015 Jun 18.